Access to medicines and treatment: latest news

Access to medicines and treatment resources

Access to medicines and treatment features

Access to medicines and treatment news from aidsmap

More news

Access to medicines and treatment news selected from other sources

  • Orban is not delivering health for Hungary

    Viktor Orban's re-election to a third consecutive term in Hungary offers a preview for western countries of what the health consequences could be for governments that value populism and economic strength over the health of their people...An OECD Country Health Profile on Hungary in 2017 offers a stark comparison with health outcomes in other European Union (EU) countries. Life expectancy in Hungary is nearly 5 years below the EU average...lower than all of Hungary's immediate neighbours with the exception of Romania. Under Orban's leadership, the number of new cases of HIV/AIDS has more than doubled in a decade, rising from 1·0 per 100 000 in 2005 to 2·7 per 100 000 in 2015.

    21 April 2018 | The Lancet
  • Antiretroviral shortage reaches 100% in Venezuela

    Alberto Nieves, executive director of Acción Ciudadana Contra el SIDA (ACCSI) says: "By March 2018, the shortage of antiretroviral drugs reached 100% in Venezuela, which It is affecting more than 80 thousand people with HIV." Four of the 27 licensed antiretrovirals were still in stock but not ones necessary to construct viable combination therapy.

    17 April 2018 | Corresponsales Clave
  • ARV stock-outs kill more Ugandans

    “Of recent, HIV drug stock-out is adding a lot of misery to us as service providers in the ART clinics because we get very few drugs from National Medical Stores (NMS) which is not enough for our patients. We keep on begging for drugs from nearby health centres. When patients spend long time without taking drugs, they develop resistance,” Dr Peter Andrew Kalema said.

    12 April 2018 | The Observer
  • A Cheaper Version of Truvada Is Hitting the US Market: Here's Why It Might Not Lower Costs

    Coming to U.S. pharmacies this month is Cimduo, from drugmaker Mylan. It's essentially a copycat of Truvada (TDF/FTC), but there's good reason to believe that, despite its lower price, Mylan just won't catch on. And the reasons point to the bigger issue of why it's so hard in general to bring down to earth the price of HIV drugs.

    04 April 2018 | The Body
  • Why are there still so many AIDS-related deaths?

    A friend of mine, Antron-Reshaud Olukayode, died of an AIDS-related illness a few months ago. He was an Atlanta-based writer and HIV advocate. The news was quite a shock for me because an empowered person living with HIV isn’t supposed to die at age 33. Or so I believed.

    03 April 2018 | Poz
  • Generation PrEP?

    Pre-exposure prophylaxis has an uncertain future among youth under 25. A litany of variables, both internal and logistical, can keep MSM of any age from accessing PrEP. These factors are often magnified by adolescence, a period during which individuals are less certain of their sexual orientation, less engaged in the health care system and less likely to adhere to a daily drug regimen.

    03 April 2018 | Poz
  • Every day, 170 young people are infected with HIV in West and Central Africa, and many can't afford treatment

    West and Central Africa, 80% of infected children are not receiving antiretroviral therapy, making it the region with the world's lowest rate of access to treatment. The number of 15- to 19-year-olds dying of AIDS in West and Central Africa increased by 35% between 2010 and 2016, even while it fell elsewhere across the continent.

    03 April 2018 | Los Angeles Times
  • We are creating new inequities around PrEP

    I was bemused this week to see community orgs trumpeting a ‘huge victory’ in securing PBS listing for PrEP from 1st April. The mandatory PBS copayment is $39.50, or $6.40 if you receive a Centrelink payment and have a healthcare card (HCC). However the priority for prevention strategy is making PrEP widely available for free.

    26 March 2018 | Bad Blood
  • Gay men seeking HIV-preventing PrEP drugs are being ‘turned away’ from sexual health clinics over trial capacity

    More than two dozen sexual health clinics in England are now turning away gay men who are seeking to take HIV-preventing drugs, PinkNews has found.

    21 March 2018 | Pink News
  • A guide for migrants in the face of concerted dehumanisation

    Today, MRN is launching a Know Your Rights guide for migrants. We want to help migrants understand and assert their rights in a context where these are being systematically eroded and routinely denied.

    14 March 2018 | Migrants' Rights Network
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.